Physician profile
Alonso Alvarez
NPI 1952502650
$4,346.54
in general payments reported to CMS, 2019-2025
35 companies · $484 in 2025
The $484 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $463 · 2021: $1,001 · 2022: $378 · 2023: $668 · 2024: $581 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,151.50 | 2019-2025 | Ams 700, General - Therapies, Spaceoar Vue System - 10ml |
| Axonics, INC. | $860.65 | 2020-2023 | Axonics |
| Astellas Pharma US INC | $547.15 | 2019-2024 | Xtandi |
| Procept Biorobotics Corporation | $284.60 | 2021-2025 | Aquabeam System, Aquabeam Robotic System |
| Sumitomo Pharma America, INC. | $220.22 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $198.04 | 2020-2025 | |
| Abbvie INC. | $151.75 | 2019-2024 | |
| Tolmar, INC. | $70.28 | 2025 | Eligard |
| Coloplast Corp | $70.18 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.94 | 2019-2023 | |
| Blue Earth Diagnostics | $69.22 | 2024-2025 | Posluma |
| Amgen INC. | $68.48 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $57.74 | 2020-2024 | Xiaflex |
| Endo USA, INC. | $48.42 | 2024 | Xiaflex |
| Karl Storz Endoscopy-America | $42.39 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $37.18 | 2021-2022 | |
| Baxter Healthcare | $31.90 | 2025 | Tisseel |
| Merck Sharp & Dohme LLC | $31.79 | 2024 | Keytruda |
| Dendreon Pharmaceuticals LLC | $30.36 | 2023 | Provenge |
| Ferring Pharmaceuticals INC. | $29.00 | 2019-2025 | Adstiladrin |
| Intuitive Surgical, INC. | $21.98 | 2020 | |
| Metuchen Pharmaceuticals | $21.15 | 2019 | |
| Ethicon US, LLC | $21.01 | 2019 | |
| Olympus America INC. | $21.00 | 2024 | Itind System |
| Travere Therapeutics, INC. | $20.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.49 | 2025 | |
| Teleflex LLC | $20.04 | 2023 | Urolift |
| Cycle Pharmaceuticals INC | $19.10 | 2025 | Venxxiva |
| Astrazeneca Pharmaceuticals LP | $18.68 | 2022 | |
| Angiodynamics, INC. | $17.52 | 2022 | |
| Urovant Sciences INC | $16.89 | 2022 | |
| Myriad Genetic Laboratories, INC. | $16.51 | 2022 | |
| Verity Pharmaceuticals INC. | $14.43 | 2023 | Trelstar |
| Isoray, INC | $13.43 | 2022 | |
| Allergan, INC. | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alonso Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.